tipifarnib has been researched along with Squamous Cell Carcinoma of Head and Neck in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Chen, ZG; El-Deiry, M; Griffith, CC; Nannapaneni, S; Patel, M; Saba, NF; Shin, DM; Shu, L; Sun, Y; Wang, D; Wang, X | 1 |
| Adkins, DR; Bruce, JY; Burrows, F; Chan, S; Dale, S; Dayoub, A; Gascó Hernández, A; Gutkind, JS; Hanna, GJ; Ho, AL; Kessler, L; Koshizuka, K; Malik, S; McCloskey, A; Patel, HV; Perez, CA; Reilly, Q; Saunders, A; Smith, AE; Soifer, HS; Villaflor, V; Wang, JZ; Wang, Z | 1 |
| Grandis, JR; Johnson, DE; Lee, RH | 1 |
| Burrows, F; Calleja-Valera, JL; Chillà, A; Ferrara, N; Gilardi, M; Goto, Y; Gualberto, A; Gutkind, JS; Janes, MR; Mikulski, Z; Molinolo, AA; Proietto, M; Vanoni, M; Wang, Z | 1 |
4 other study(ies) available for tipifarnib and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
Topics: Animals; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Mice; Quinolones; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2021 |
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Topics: Biomarkers; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras); Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases | 2023 |
To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Precision Medicine; Proto-Oncogene Proteins p21(ras); Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases | 2023 |
Tipifarnib as a Precision Therapy for
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Head and Neck Neoplasms; Humans; Male; MAP Kinase Signaling System; Mice; Mutation; Precision Medicine; Prenylation; Proto-Oncogene Proteins p21(ras); Quinolones; Sequence Analysis, RNA; Squamous Cell Carcinoma of Head and Neck | 2020 |